These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24385319)

  • 1. MicroRNA-targeting therapeutics for hepatitis C.
    Baek J; Kang S; Min H
    Arch Pharm Res; 2014 Mar; 37(3):299-305. PubMed ID: 24385319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered microRNA therapeutics.
    Gibson NW
    J R Coll Physicians Edinb; 2014; 44(3):196-200. PubMed ID: 25318394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense gets a grip on miR-122 in chimpanzees.
    Branch AD; Rice CM
    Sci Transl Med; 2010 Jan; 2(13):13ps1. PubMed ID: 20371461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma.
    Young DD; Connelly CM; Grohmann C; Deiters A
    J Am Chem Soc; 2010 Jun; 132(23):7976-81. PubMed ID: 20527935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roadmap of miR-122-related clinical application from bench to bedside.
    Qiu Z; Dai Y
    Expert Opin Investig Drugs; 2014 Mar; 23(3):347-55. PubMed ID: 24354366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis.
    Gelley F; Zadori G; Nemes B; Fassan M; Lendvai G; Sarvary E; Doros A; Gerlei Z; Nagy P; Schaff Z; Kiss A
    J Gastroenterol Hepatol; 2014 Jan; 29(1):121-7. PubMed ID: 24033414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovering the first microRNA-targeted drug.
    Lindow M; Kauppinen S
    J Cell Biol; 2012 Oct; 199(3):407-12. PubMed ID: 23109665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion.
    Goldaracena N; Spetzler VN; Echeverri J; Kaths JM; Cherepanov V; Persson R; Hodges MR; Janssen HL; Selzner N; Grant DR; Feld JJ; Selzner M
    Am J Transplant; 2017 Apr; 17(4):970-978. PubMed ID: 27805315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.
    Gebert LF; Rebhan MA; Crivelli SE; Denzler R; Stoffel M; Hall J
    Nucleic Acids Res; 2014 Jan; 42(1):609-21. PubMed ID: 24068553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of HCV infection by targeting microRNA.
    Janssen HL; Reesink HW; Lawitz EJ; Zeuzem S; Rodriguez-Torres M; Patel K; van der Meer AJ; Patick AK; Chen A; Zhou Y; Persson R; King BD; Kauppinen S; Levin AA; Hodges MR
    N Engl J Med; 2013 May; 368(18):1685-94. PubMed ID: 23534542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway.
    Ishida H; Tatsumi T; Hosui A; Nawa T; Kodama T; Shimizu S; Hikita H; Hiramatsu N; Kanto T; Hayashi N; Takehara T
    Biochem Biophys Res Commun; 2011 Aug; 412(1):92-7. PubMed ID: 21802413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of hepatitis C virus replicon by adenovirus vector-mediated expression of tough decoy RNA against miR-122a.
    Sakurai F; Furukawa N; Higuchi M; Okamoto S; Ono K; Yoshida T; Kondoh M; Yagi K; Sakamoto N; Katayama K; Mizuguchi H
    Virus Res; 2012 May; 165(2):214-8. PubMed ID: 22342424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Overview of locked nucleic acid(LNA)- SPC3649 and its application in HCV treatment].
    Zhang L; Tan WJ
    Bing Du Xue Bao; 2011 Nov; 27(6):614-8. PubMed ID: 22263277
    [No Abstract]   [Full Text] [Related]  

  • 14. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection.
    Nunnari G; Schnell MJ
    Front Biosci (Schol Ed); 2011 Jun; 3(3):1032-7. PubMed ID: 21622252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The liver-specific microRNA miR-122: biology and therapeutic potential.
    Filipowicz W; Grosshans H
    Prog Drug Res; 2011; 67():221-38. PubMed ID: 21141732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma.
    van der Ree MH; van der Meer AJ; van Nuenen AC; de Bruijne J; Ottosen S; Janssen HL; Kootstra NA; Reesink HW
    Aliment Pharmacol Ther; 2016 Jan; 43(1):102-13. PubMed ID: 26503793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes.
    Banaudha K; Kaliszewski M; Korolnek T; Florea L; Yeung ML; Jeang KT; Kumar A
    Hepatology; 2011 Jan; 53(1):53-61. PubMed ID: 20967756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-122 in hepatic function and liver diseases.
    Hu J; Xu Y; Hao J; Wang S; Li C; Meng S
    Protein Cell; 2012 May; 3(5):364-71. PubMed ID: 22610888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA miR-122 as a therapeutic target for oligonucleotides and small molecules.
    Thomas M; Deiters A
    Curr Med Chem; 2013; 20(29):3629-40. PubMed ID: 23745562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.